Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SALUTE: Treat and Extend vs Labeled Ranibizumab in AMD
NCT01148511Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2010
- Primary completion
- Apr 2012
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ranibizumab in age-related macular degeneration (AMD) and choroidal neovascularization (CNV) (2 arms), sponsored by Novartis. Primary endpoints: Change in Best-Corrected Visual Acuity (logMAR) at 12 months and Change in Letter Count at 12 months. Started Feb 2010; status: completed.
02
Drugs
ranibizumab
03
Conditions
age-related macular degeneration (AMD)choroidal neovascularization (CNV)
Beyond the preview
Go deeper on NCT01148511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01148511.